{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:01:41Z","timestamp":1780506101582,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,6]]},"DOI":"10.7759\/cureus.16933","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T10:13:51Z","timestamp":1628244831000},"source":"Crossref","is-referenced-by-count":4,"title":["Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen"],"prefix":"10.7759","author":[{"given":"Nikole","family":"Figueroa-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepinder","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Anjum Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwanath","family":"Pattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe DD","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, et al.. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008, 14:7272-83. 10.1158\/1078-0432.CCR-08-0652","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins MB","year":"2018","unstructured":"Atkins MB, Plimack ER, Puzanov I, et al.. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018, 19:405-15. 10.1016\/S1470-2045(18)30081-0","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034626","article-title":"What is the optimum systemic treatment for advanced\/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis","volume":"10","author":"Cao G","year":"2020","unstructured":"Cao G, Wu X, Wang Z, et al.. What is the optimum systemic treatment for advanced\/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. BMJ Open. 2020, 10:10.1136\/bmjopen-2019-034626","journal-title":"BMJ Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino M","year":"2018","unstructured":"Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer. Respirol Case Rep. 2018, 6:10.1002\/rcr2.355","journal-title":"Respirol Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey AC","year":"2017","unstructured":"Paepegaey AC, Lheure C, Ratour C, et al.. Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma. J Endocr Soc. 2017, 1:646-9. 10.1210\/js.2017-00170","journal-title":"J Endocr Soc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9637-1","article-title":"Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients","volume":"30","author":"Fujiwara Y","year":"2012","unstructured":"Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs. 2012, 30:1055-64. 10.1007\/s10637-011-9637-1","journal-title":"Invest New Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys076","article-title":"Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma","volume":"42","author":"Daimon M","year":"2012","unstructured":"Daimon M, Kato T, Kaino W, et al.. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012, 42:742-7. 10.1093\/jjco\/hys076","journal-title":"Jpn J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01465.x","article-title":"Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients","volume":"101","author":"Mukohara T","year":"2010","unstructured":"Mukohara T, Nakajima H, Mukai H, et al.. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010, 101:963-8. 10.1111\/j.1349-7006.2009.01465.x","journal-title":"Cancer Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000505687","article-title":"A case of isolated adrenocorticotropic hormone deficiency caused by pembrolizumab","volume":"13","author":"Bekki T","year":"2020","unstructured":"Bekki T, Takakura Y, Kochi M, et al.. A case of isolated adrenocorticotropic hormone deficiency caused by pembrolizumab. Case Rep Oncol. 2020, 13:200-6. 10.1159\/000505687","journal-title":"Case Rep Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-32. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-019-0092-9","article-title":"Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report","volume":"6","author":"Tanaka S","year":"2020","unstructured":"Tanaka S, Kushimoto M, Nishizawa T, et al.. Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. Clin Diabetes Endocrinol. 2020, 6:1. 10.1186\/s40842-019-0092-9","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13499","article-title":"Pembrolizumab-associated ocular myasthenia gravis","volume":"47","author":"Liu Q","year":"2019","unstructured":"Liu Q, Ayyappan S, Broad A, Narita A. Pembrolizumab-associated ocular myasthenia gravis. Clin Exp Ophthalmol. 2019, 47:796-8. 10.1111\/ceo.13499","journal-title":"Clin Exp Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2019.02.003","article-title":"Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy","volume":"94","author":"Zekeridou A","year":"2019","unstructured":"Zekeridou A, Lennon VA. Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc. 2019, 94:1865-78.","journal-title":"Mayo Clin Proc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang YT","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020, 11:634. 10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/JIPO.JIPO_15_18","article-title":"Cardiotoxicity of FDA-approved immune checkpoint inhibitors: a rare but serious adverse event","volume":"1","author":"Zarifa A","year":"2018","unstructured":"Zarifa A, Salih M, Lopez-Mattei J, et al.. Cardiotoxicity of FDA-approved immune checkpoint inhibitors: a rare but serious adverse event. J Immunother Precis Oncol. 2018, 1:68-77. 10.4103\/JIPO.JIPO_15_18","journal-title":"J Immunother Precis Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling L","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, et al.. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016, 4:50. 10.1186\/s40425-016-0152-y","journal-title":"J Immunother Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0255-17","article-title":"Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring","volume":"57","author":"Katsume Y","year":"2018","unstructured":"Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T. Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med. 2018, 57:3157-62. 10.2169\/internalmedicine.0255-17","journal-title":"Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/64040-autoimmune-myasthenia-primary-adrenal-insufficiency-and-progressive-hypothyroidism-due-to-pembrolizumab-and-axitinib-combination-regimen","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:05Z","timestamp":1707507185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/64040-autoimmune-myasthenia-primary-adrenal-insufficiency-and-progressive-hypothyroidism-due-to-pembrolizumab-and-axitinib-combination-regimen"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.16933","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,6]]}}}